Free website hits

Hello, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. The short person is hunched over the laptop and the official mascot has finally withdrawn to the official snoozing corner. This means we are free to pursue the important tasks — brewing cups of stimulation (our choice today is blueberry) and foraging for items of interest. Speaking of which, here are a few tidbits. We hope your day goes well and you survive any tumult. Meanwhile, stay in touch and stay safe. …

Food and Drug Administration staff said that data on the Pfizer (PFE) Covid-19 vaccine were in line with its guidance on emergency use authorization, raising hopes it could soon be available to Americans aged 16 and older, Reuters says. The comments were made in documents released ahead of a meeting on Thursday of an FDA advisory panel to discuss whether the vaccine, which was developed with BioNTech (BNTX), should be authorized for emergency use. The FDA is expected to decide whether to authorize the vaccine within days or weeks.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]